STOCK TITAN

Inotiv Inc - NOTV STOCK NEWS

Welcome to our dedicated page for Inotiv news (Ticker: NOTV), a resource for investors and traders seeking the latest updates and insights on Inotiv stock.

Overview of Inotiv Inc

Inotiv Inc is a comprehensive pharmaceutical development entity that specializes in delivering nonclinical and analytical drug discovery and development services. Operating across a spectrum of industries including pharmaceuticals, chemicals, and medical devices, the company is known for its integrated approach and suite of research models, laboratory instrumentation, and contract research offerings. Key industry keywords such as "nonclinical research", "drug discovery" and "analytical services" underscore its commitment to advancing scientific innovation and meeting the needs of its diverse clientele.

Core Business Segments

The company operates through two critical segments:

  • Discovery and Safety Assessment (DSA): This segment supports every stage of the drug and device development process by providing essential nonclinical research services, safety assessments and analytical testing. It plays a pivotal role in advancing small molecule drug candidates, biotherapeutics, and biomedical technologies from the discovery phase into clinical development.
  • Research Models and Services (RMS): Focused on offering a broad range of research models—from small laboratory setups to extensive large-scale systems—this segment underpins basic research and specialized studies in disease-specific areas. Researchers rely on these models to conduct in vivo studies, pharmacokinetic investigations, and various analytical evaluations essential during preclinical development.

Operational Excellence and Business Model

Inotiv Inc has crafted a reputation for operational excellence by combining state-of-the-art laboratory instrumentation with a deep understanding of regulatory requirements and client needs. The company’s business model leverages direct service offerings, integrated research solutions and advanced scientific instrumentation, such as automated in vivo sampling systems that support behavioral and biological data collection in freely-moving subjects. Its emphasis on efficiency and quality helps clients meet critical milestones in their research and development projects.

Industry Significance and Competitive Edge

Positioned within the highly competitive contract research organization space, Inotiv stands out through its strategic integration of comprehensive services and innovative technological tools. By blending its Discovery and Safety Assessment capabilities with extensive research model resources, the company offers a unique value proposition that addresses the evolving requirements of pharmaceutical and medical device research. This integration enables a streamlined approach that reduces the complexities of transitioning from basic research to clinical development, thereby minimizing delays and promoting more reliable data generation.

Expertise, Quality, and Regulatory Compliance

The company is distinguished by its robust regulatory track record and commitment to quality and compliance. Through continuous improvements in laboratory practices, facility optimizations and adherence to animal welfare standards, Inotiv demonstrates its commitment to maintaining the highest levels of scientific integrity and ethical standards. This is critical in an environment where precision and adherence to safety protocols are essential for the successful development of new therapies and medical devices.

Comprehensive Service Offerings

Inotiv Inc’s service portfolio is designed to support customers through every step in their research and development journey. From preclinical toxicology and early in vivo pharmacokinetics to bioanalysis and full-spectrum pharmaceutical analysis, the company’s services are built around enabling groundbreaking research. Furthermore, its production of innovative scientific instruments provides researchers with the necessary tools to generate high-quality and reproducible data in a fast-paced development environment.

Market Position and Client Focus

By addressing the comprehensive needs of drug discovery and development, Inotiv has carved out a significant niche in the life sciences sector. Its dual-segment approach facilitates a full-service offering that bridges the gap between early-stage discovery and later-phase preclinical research. Accepting a wide range of client requirements, from small laboratories to larger research institutions, Inotiv’s client-centric philosophy is embedded in its operational practices, ensuring that client objectives are met through scientifically rigorous, timely and cost-effective solutions.

Conclusion

In summary, Inotiv Inc is an established force in pharmaceutical research support, leveraging its nonclinical expertise and analytical capabilities to enhance the drug and device development process. Its strategic service integration, commitment to regulatory compliance and innovative approach to scientific instrumentation solidify its role as a trusted partner for clients seeking to navigate the complexities of modern drug discovery and development.

Rhea-AI Summary

Inotiv, Inc. (Nasdaq: NOTV) has amended its Credit Agreement and secured additional liquidity through the sale of $22.6 million in 15% Senior Secured Second Lien PIK Notes due February 2027. The company also issued warrants to purchase common shares. This move aims to increase liquidity and strengthen Inotiv's balance sheet. The Credit Agreement amendment provides financial covenant relief through June 30, 2025, and establishes new covenant tests thereafter.

CEO Robert Leasure Jr. stated that this will give Inotiv more flexibility to see results from recent site optimization plans, NHP market recovery, and efforts to grow market share and cashflow. The company continues to focus on improving customer experience, organic revenue growth, and evaluating opportunities to enhance its balance sheet.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.97%
Tags
none
-
Rhea-AI Summary

Inotiv (Nasdaq: NOTV), a leading contract research organization, announced its participation in the 8th Annual Lake Street Best Ideas Growth Conference on September 12, 2024, in New York City. Robert Leasure Jr., President and CEO, and Beth Taylor, CFO, will represent the company at the event.

The conference provides an opportunity for Inotiv's management to host one-on-one meetings with investors and attendees. This engagement allows the company to showcase its expertise in nonclinical and analytical drug discovery and development services, as well as its offerings in research models and related products.

Investors interested in arranging meetings with Inotiv's leadership should contact their Lake Street conference representative to schedule appointments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.29%
Tags
conferences
-
Rhea-AI Summary

Inotiv (NOTV) reported Q3 FY2024 financial results, with revenue down 32.8% to $105.8 million. Key highlights include:

  • YTD fiscal 2024 revenue down 16.5% to $360.3 million
  • Q3 net loss of $26.1 million, compared to $0.4 million net income in Q3 FY2023
  • Adjusted EBITDA of $0.1 million in Q3 FY2024, down from $30.5 million in Q3 FY2023
  • DSA backlog at $139.4 million, down from $149.1 million year-over-year
  • Conclusion of certain government investigations
  • Completion of site optimization projects

The company faced challenges due to lower non-human primate demand and pricing, but sees signs of recovery in various segments of its business.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
Rhea-AI Summary

Inotiv, Inc. (NASDAQ: NOTV), a leading contract research organization, has announced it will release its fiscal 2024 third quarter financial results on Thursday, August 8, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested parties can participate by dialing 1-800-225-9448 (Domestic) or 1-203-518-9708 (International) with the Conference ID: INOTIV. A live webcast will be available on the company's website, and a replay will be accessible in the Investors section for those unable to attend the live broadcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
conferences earnings
-
News
Rhea-AI Summary

Inotiv, a leading contract research organization (CRO), has completed its Hillcrest, U.K. expansion project. This expansion allows two new customers to start their long-term contracts and enables the transfer of operations from the Blackthorn facility to Hillcrest by September 2024.

Inotiv has also extended the maturity date of its $3.7 million OBRC payable note to July 2025, which will start accruing interest at 4.6% per annum from July 2024. CEO Robert Leasure Jr. highlighted these steps as part of the company's transformation plan initiated in 2022, focusing on growth, efficiency, and improvements in infrastructure and animal welfare.

The company aims to ramp up sales and marketing efforts and develop new services, positioning itself as a global mid-sized CRO. The consolidation and integration projects are expected to yield efficiency gains.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.43%
Tags
none
-
Rhea-AI Summary

Inotiv has reached an agreement with the U.S. Department of Justice to resolve a criminal investigation into the closed canine breeding facility in Cumberland, Virginia, initially operated by Envigo RMS. Envigo RMS and Envigo Global Services pleaded guilty to charges related to the Animal Welfare Act and the Clean Water Act, respectively. The resolution includes $22 million in fines, payable over four years, and a commitment to invest $7 million in animal welfare improvements. Additionally, Inotiv has paid $6.5 million towards various environmental and animal welfare initiatives and agreed to non-monetary conditions. This agreement aims to eliminate uncertainty and allow Inotiv to focus on its core business of drug discovery and development services while reinforcing its dedication to animal welfare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.04%
Tags
none
Rhea-AI Summary

Inotiv (Nasdaq: NOTV) announced participation in the 21st Annual Craig Hallum Institutional Investor Conference in Minneapolis on May 29, 2024, and the Jefferies Global Healthcare Conference in New York from June 4-6, 2024. Key executives, including CEO Robert Leasure Jr. and CFO Beth Taylor, will engage in one-on-one meetings and presentations aimed at institutional investors, with a notable presentation at 10:30 AM ET on June 6, 2024. Investors can schedule meetings via their sales reps at Craig Hallum and Jefferies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
conferences
-
Rhea-AI Summary

Inotiv (NASDAQ: NOTV) reported a 21.5% decline in Q2 fiscal 2024 revenue, amounting to $119.0 million, driven by reduced demand in Research Models and Services (RMS). Year-to-date revenue also fell by 7.2% to $254.5 million. The company's consolidated net loss for Q2 FY 2024 reached $48.1 million, significantly impacted by a $26.5 million charge related to an agreement in principle with the U.S. Department of Justice (DOJ). Adjusted EBITDA for Q2 FY 2024 was $3.1 million. Management noted weak non-human primate (NHP) demand and ongoing site optimization projects. The company has withdrawn its fiscal 2024 outlook due to uncertain NHP demand but continues to focus on long-term strategic goals, including expense reduction and revenue growth initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
-
Rhea-AI Summary

Inotiv (NASDAQ: NOTV), a prominent contract research organization, will release its fiscal 2024 Q2 financial results on May 15, 2024, after market close. The results will cover the period ending March 31, 2024.

Following the release, the company will hold a conference call at 4:30 p.m. Eastern Time to discuss the results. Interested individuals can join the call by dialing the provided numbers or via a live webcast accessible through Inotiv's investor section.

A replay will also be available online for those unable to attend the live session.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-49.16%
Tags
conferences earnings
Rhea-AI Summary

Inotiv, Inc. (Nasdaq: NOTV) reschedules its Fiscal 2024 Second Quarter Results to complete accounting analyses related to an investigation by the U.S. Department of Justice. The Company is working on a potential resolution with the DOJ, leading to a delay in the release of financial results and the conference call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.62%
Tags

FAQ

What is the current stock price of Inotiv (NOTV)?

The current stock price of Inotiv (NOTV) is $2.76 as of April 3, 2025.

What is the market cap of Inotiv (NOTV)?

The market cap of Inotiv (NOTV) is approximately 85.0M.

What are the core business segments of Inotiv Inc?

Inotiv Inc operates through two main segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment focuses on nonclinical and analytical services for drug development, while the RMS segment provides diverse research models for basic and specialized studies.

Which industries does Inotiv Inc serve?

Inotiv Inc serves a broad range of industries including pharmaceuticals, chemicals, and medical devices. Its services cater to both biotherapeutics and small molecule drug candidates, as well as supporting biomedical device research.

How does Inotiv differentiate itself from competitors?

Inotiv differentiates itself by integrating advanced nonclinical and analytical services with innovative laboratory instrumentation and research models. This comprehensive approach streamlines the progression from discovery to clinical development and complies with stringent regulatory standards.

What type of research models does Inotiv offer?

Inotiv offers a wide array of research models, ranging from small and large-scale models for basic research to specialized models for disease-specific studies. These models are essential for pharmacokinetic assessments, in vivo studies, and other preclinical evaluations.

What role does regulatory compliance play in Inotiv's operations?

Regulatory compliance is a cornerstone of Inotiv's operations. The company maintains a strong track record of adhering to safety standards and ethical practices, which reinforces its credibility and ensures quality in all research and developmental activities.

How does Inotiv support the drug discovery process?

Inotiv supports the drug discovery process by offering a full suite of services that include preclinical toxicology, early in vivo pharmacokinetics, bioanalysis, and comprehensive pharmaceutical analysis. This integrated support helps reduce development timelines and improves data reliability.

What technological innovations does Inotiv incorporate in its services?

The company leverages advanced technological tools such as automated in vivo sampling systems and specialized analytical equipment. These innovations enhance data collection, improve efficiency and support high-quality research outputs essential for effective drug development.
Inotiv Inc

Nasdaq:NOTV

NOTV Rankings

NOTV Stock Data

85.01M
29.26M
11.14%
26.64%
5.78%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States
WEST LAFAYETTE